斯達(dá)特(Starter)，國(guó)產(chǎn)抗體專家，
產(chǎn)品別名: CD155/PVR Recombinant Rabbit mAb (SDT-289-68)

Poliovirus receptor (PVR, CD155), a member of the nectin-like family of proteins, is recently emerging as a promising target in immunotherapy that enhances the existing anti-tumor responses. Similar to other members of the family, PVR is involved in important cellular processes, such as adhesion, contact inhibition, migration, proliferation, and the immune response [PMID: 18648374]. PVR is dramatically overexpressed in several human malignancies, whereas its expression is low or absent in most healthy tissues [PMID: 10841575, PMID: 11454801, PMID: 15604290, PMID: 15536144, PMID: 19801517]. Consistent with PVR biology, its overexpression promotes tumor cell invasion, migration, and proliferation and is associated with a poor prognosis and enhanced tumor progression [PMID: 16322240, PMID: 17893876, PMID: 25743219, PMID: 25862891]. Simultaneously, PVR has a considerable immunoregulatory potential. It interacts with the (co)stimulatory receptor DNAM-1 and the inhibitory receptors TIGIT and CD96, resulting in either immune cell activation or inhibition, respectively [PMID: 28870470].

杭州斯達(dá)特專注于抗體研發(fā)和制造，其核心團(tuán)隊(duì)深耕抗體研發(fā)十五年，提供優(yōu)質(zhì)的抗體、蛋白、試劑盒和定制服務(wù)，包括科研抗體、CDx和IVD抗原和抗體原料、一步法ELISA試劑盒、鼠兔通用二抗試劑盒以及其他用途的免疫試劑整體解決方案。公司建立了多物種單B細(xì)胞抗體開發(fā)平臺(tái)（兔單抗，鼠類單抗等）、傳統(tǒng)鼠單抗、重組蛋白表達(dá)平臺(tái)及完善的抗體應(yīng)用驗(yàn)證和檢測(cè)體系（包括免疫層析，酶聯(lián)免疫，流式分析，免疫組化，免疫印跡，免疫熒光，免疫沉淀等）。已正式通過(guò)歐盟98/79/EC認(rèn)證、ISO9001認(rèn)證和ISO13485認(rèn)證。 官網(wǎng)點(diǎn)擊查詢：www.starter-bio.com